The iBio Technology has been validated by major industry players, as well as the Brazilian government, opening iBio’s doorway to the world market.
With extensive patent protection and proprietary know-how, iBio creates a high barrier to entry for competitors.
iBio’s global commercialization program, which was started in the favorable Brazilian market, is also licening the iBio Technology to key U.S. companies.
The iBio Technology platform is a proprietary gene expression technology that causes non-transgenic plants to rapidly produce high levels of target proteins and has been validated across a wide range of applications in both vaccines and biotherapeutics.

Type
Public
HQ
Newark, US
Founded
2008
Employees
7 (est)
iBio was founded in 2008 and is headquartered in Newark, US

iBio Locations

Newark, US

iBio Metrics

iBio Summary

Market capitalization

$36.5 M

Closing share price

$0.43
iBio's latest market capitalization is $36.5 M.

iBio Market Value History

iBio Company Life

You may also be interested in